Zika virus, a mosquito-borne virus that is explosively spreading, 1.6+ million infections reported, causes microcephaly birth defects. Dengue virus, a life-debilitating, potentially deadly mosquito-borne virus that infects 400 million people, hospitalizes 1.5 million and kills 100,000+ annually.
Ennaid Therapeutics is developing an orally deliverable anti-viral peptide that treats and prevents Zika virus and has 9+ additional indications to treat and prevent the following viruses: dengue, chikungunya, West Nile, hepatitis c, yellow fever, tick-borne encephalitis, Japanese encephalitis, European encephalitis, Kyasanur Forest virus.
We welcome strategic partnerships, as partnerships accelerate the development of our cures from the lab to the people who need them.
CEO and President
Vice President & Chief Operating Officer
Scientific Advisory Board
Chief Scientific Officer, Inventor & Board of Directors